Medically reviewed by Dr Nabila Laskar, Consultant Cardiologist (GMC 7040901). Left ventricular hypertrophy (LVH) refers to thickening of the muscular wall of the left ventricle, the heart's main pumping chamber. It is a response to sustained increased workload, most commonly caused by long-standing high blood pressure, and carries an independently elevated cardiovascular risk.
The most common cause by far is sustained hypertension. When the left ventricle must pump against elevated pressure over years, its muscle wall thickens in response, similar to how any muscle hypertrophies under repeated load. Other causes include aortic stenosis (the valve the left ventricle pumps through is narrowed, increasing resistance), hypertrophic cardiomyopathy (an inherited genetic condition causing disproportionate thickening), and long-term intensive athletic training (physiological hypertrophy, which is distinct from pathological LVH). Distinguishing these causes from one another requires specialist echocardiographic assessment.
LVH is not simply a structural finding without clinical consequence. It is an independent risk factor for atrial fibrillation, heart failure, ventricular arrhythmias, and sudden cardiac death. The thickened, stiffer ventricle fills less efficiently between beats (diastolic dysfunction), and over time its pumping function can decline. Regression of LVH with appropriate blood pressure treatment is associated with a meaningful reduction in these risks, which is one reason treating hypertension aggressively matters beyond just the blood pressure numbers themselves.
An ECG may suggest LVH through voltage criteria, though sensitivity is limited. Echocardiography is the gold standard: it directly measures the interventricular septum and posterior wall thickness at defined points in the cardiac cycle, calculates left ventricular mass, and assesses diastolic function and overall pumping performance. These measurements determine whether thickening is within the range of physiological adaptation or represents pathological hypertrophy requiring further investigation and treatment.
Where LVH is caused by hypertension, the primary treatment is blood pressure control. Certain antihypertensive classes, particularly ACE inhibitors, ARBs, and calcium channel blockers, have evidence for LVH regression beyond their blood-pressure-lowering effect. Serial echocardiograms monitor whether wall thickness is regressing, stable, or progressing. Where LVH is caused by hypertrophic cardiomyopathy, management follows the HCM pathway with its own specific risk stratification approach.
No, though both involve a thickened left ventricle. Hypertensive LVH is typically concentric and proportionate. HCM involves asymmetric, disproportionate thickening with a genetic cause. Distinguishing them requires specialist echocardiographic assessment and clinical context.
LVH from hypertension can regress significantly with sustained blood pressure control using appropriate medication. Reversal reduces cardiovascular risk independently of the blood pressure reduction itself.
Mild LVH is often asymptomatic and found on routine assessment. More significant LVH can contribute to breathlessness on exertion, fatigue, palpitations, and reduced exercise tolerance as diastolic function declines.
A left ventricular wall thickness above 12mm is generally considered above the upper limit of normal in adults, though reference ranges account for body size. Your cardiologist will interpret your specific measurements in context.